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Leptin has not evolved as a therapeutic modality for
the treatment of obesity due to the prevalence of lep-
tin resistance in a majority of the obese population.
Nevertheless, the molecular mechanisms of leptin
resistance remain poorly understood. Here, we show
that increased endoplasmic reticulum (ER) stress
and activation of the unfolded protein response
(UPR) in the hypothalamus of obese mice inhibits lep-
tin receptor signaling. The genetic imposition of
reduced ER capacity in mice results in severe leptin
resistance and leads to a significant augmentation of
obesity on a high-fat diet. Moreover, we show that
chemical chaperones, 4-phenyl butyric acid (PBA),
and tauroursodeoxycholic acid (TUDCA), which have
the ability to decrease ER stress, act as leptin-sensi-
tizing agents. Taken together, our results may provide
the basis for a novel treatment of obesity.
INTRODUCTION
The epidemic surge in the prevalence of obesity is one of the
most serious public health problems confronting the western
societies. Among the adult population in the United States,
65% is overweight and more than 30% is obese (Stein and Col-
ditz, 2004). There has also been an increase in the obese pedi-
atric population, with one out of three Americans born in the
year 2000 expected to suffer from the complications of obesity
in their later lifetime (Narayan et al., 2003; Rocchini, 2002).
Although causally linked to debilitating conditions such as insulin
resistance, type 2 diabetes, atherosclerosis, and cardiovascular
disease, there remains limited effective therapeutic treatment for
obesity (Muoio and Newgard, 2006).
Leptin is an adipocyte-derived hormone that suppresses
appetite mainly through its action on a subset of hypothalamic
neurons (Halaas et al., 1995; Leibel et al., 1997). It also allows
the body to expend energy necessary for growth, reproduction,
and immunity (Ahima et al., 1996; Friedman and Halaas, 1998).
Genetic leptin deficiency in mice and humans leads to a severeform of monogenic obesity due to unregulated appetite and
reduced energy expenditure (Farooqi and O’Rahilly, 2005; Gao
and Horvath, 2007; Proulx and Seeley, 2005). The discovery of
leptin more than a decade ago created hope that it might be
used therapeutically in the treatment of obesity; however, except
for rare leptin-deficient individuals, both diet-induced rodent
models of obesity and obese humans are minimally responsive
to leptin due to the development of leptin resistance in the brain
and defects in transportation of leptin across the blood brain
barrier (Banks, 2004; Elmquist et al., 1999; Flier, 2004; Schwartz
and Morton, 2002; Schwartz et al., 2000). The molecular mech-
anisms of leptin resistance are poorly understood. Suppressor
of cytokine signaling 3 (SOCS3) (Bjorbak et al., 2000; Flier,
2004; Myers, 2004) and tyrosine phosphatase 1 B (PTB1B)
have been shown to play important roles in the blockade of leptin
signaling (Bence et al., 2006). In addition, recent evidence has
demonstrated that increased serine phosphorylation of Janus
kinase 2 (Jak2) contributes to the blockade of leptin action (Ish-
ida-Takahashi et al., 2006).
The endoplasmic reticulum (ER) is a sophisticated luminal
network in which protein synthesis, maturation, folding, and
transport take place (Marciniak and Ron, 2006; Schroder
and Kaufman, 2005). Perturbation of these processes in
several different pathological states creates a condition
defined as ER stress and leads to activation of a complex
signaling network termed the unfolded protein response
(UPR) (Ron and Walter, 2007). Previous studies have demon-
strated that ER stress and activation of UPR signaling
pathways play a dominant role in the development of
obesity-induced insulin resistance and type 2 diabetes (Ozcan
et al., 2004). Furthermore, reversal of ER stress with chemical
chaperones—agents that have the ability to increase ER
folding machinery—increases insulin sensitivity and reverses
type 2 diabetes in obese mice (Ozcan et al., 2006). The mech-
anisms underlying ER stress and activation of UPR signaling
in obesity are not completely understood. Current evidence
suggests that increased levels of circulating cytokines, free
fatty acids (FFA), exposure to excess nutrition, and subse-
quent activation of the mammalian target of rapamycin
(mTOR) pathway (Ozcan et al., 2006, 2008; Ron and Walter,
2007) contribute to the development of ER stress and activa-
tion of UPR signaling pathways.Cell Metabolism 9, 35–51, January 7, 2009 ª2009 Elsevier Inc. 35
Figure 1. UPR Parameters in Hypothalamus of HFD-Fed Obese Mice
(A) UPR signaling elements phospho-PERK (Thr980) and phospho-IRE1a (Ser724) were analyzed in the hypothalamus of the male C57BL/6 WT mice fed a normal
or high-fat diet for a period of 25 weeks. (Blots are representative of three independent experiments.)
(B) PERK phosphorylation (Thr980) in the hypothalamus of the obese and nonobese HFD-fed C57BL/6 WT mice. (Blots are representative of one experiment with
three different individual mice in each group.)
(C) LepRB-expressing 293 cells were either incubated with vehicle or tunicamycin (3 mg/ml) for 4 hr and subsequently taken to leptin (100 ng/ml) stimulation for
45 min. Leptin-stimulated tyrosine phosphorylation of long-form of leptin receptor (LepRB), Janus Kinase 2 (Jak2), and signal transducers and activators of tran-
scription 3 (Stat3) (Tyr705) has been examined. (Blots are representative of more than three independent experiments.)
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ER Stress Causes Leptin ResistanceMice engineered to have reduced ER capacity (Ozcan et al.,
2004) or increased levels of ER stress (Scheuner et al., 2005)
develop a higher degree of obesity when challenged with
a high-fat diet. Because leptin-receptor-expressing neurons of
the hypothalamus are exposed to ER-stress-associated factors
such as increased FFAs and other nutrients (Myers, 2008), we
have sought to determine whether ER system is perturbed within
the hypothalamus and may contribute to the phenomenon of lep-
tin resistance and, in turn, to obesity itself.
RESULTS
Increased ER Stress in Hypothalamus of Obese Mice
To examine whether obesity creates ER stress in the hypothal-
amus, we analyzed PERK phosphorylation in hypothalamus
extracts of mice fed a normal diet (ND) or high-fat diet (HFD)
for a period of 20 weeks. PERK phosphorylation (Thr 980) was
significantly increased in hypothalami of the HFD-fed mice
when compared with ND-fed mice (Figure 1A), indicating to
a state of activated UPR. b-actin immunoblotting was performed
in the same hypothalamic extracts to confirm that protein
concentration is equal between the hypothalamic protein
samples. To demonstrate that antiserum that we used to analyze
PERK phosphorylation is specific, we treated the WT and
PERK/ mouse embryo fibroblasts with tunicamycin and
analyzed PERKThr980 phosphorylation. As shown in Figure S1
available online, the antibody specifically recognizes the phos-
phorylated PERK at Thr980 residue. To investigate whether
IRE1 was also activated in the hypothalami of the HFD group,
we analyzed IRE1 phosphorylation levels at Ser723, a phosphor-
ylation site previously shown to correlate with increased IRE1
activity. There was a significant increase in IRE1 phosphorylation
in the hypothalami of HFD-fed group when compared with the
ND-fed lean group (Figure 1A). Taken together, the data pre-
sented above indicate that obesity creates ER stress in the hypo-
thalamus. Indeed, a recent publication has also demonstrated
that PERK phosphorylation is increased in the hypothalamus of
the obese mice (Zhang et al., 2008).
To examine whether ER stress generally occurs in the hypo-
thalamus of the HFD-fed mice regardless of obesity or mainly
develops in the mice, which develops obesity, we placed
a cohort of C57BL/6 male mice on HFD at the age of 3 weeks.
Following 8 weeks of HFD feeding, we chose the mice with
high and low body weights and analyzed the PERK phosphory-
lation in hypothalamus extracts of these mice. PERK phosphor-
ylation is markedly upregulated in the hypothalami of the mice
that have developed obesity, but not in the group that has not
developed obesity (Figure 1B). These results indicate that devel-
opment of obesity correlates with the development of ER stress
in the hypothalamus.
ER Stress Inhibits Leptin Receptor Signaling
The long form of leptin receptor (LepRB) has been shown to
mediate the anorexigenic effect of leptin in the central nervous
system. To examine whether UPR might alter the leptin signaling,
LepRB-expressing 293 cells were first exposed to tunicamycin
(3 mg/ml) to activate ER stress for a period of 4 hr and then
treated with leptin (100 ng/ml) for 45 min. Stimulation of
DMSO-treated 293 cells with leptin led to a marked increase in
LepRB tyrosine phosphorylation (Figure 1C). However, pretreat-
ment of the cells with tunicamycin completely inhibited leptin-
stimulated tyrosine phosphorylation of LepRB without altering
the total protein levels (Figure 1C). Next, we analyzed Jak2 tyro-
sine phosphorylation; as with LepRB, the leptin-stimulated Jak2
tyrosine phosphorylation was reduced to an undetectable level
when the cells were subjected to ER stress (Figure 1C). Finally,
as a downstream element, leptin-stimulated Stat3 activation
was analyzed. As previously reported (Kloek et al., 2002), stimu-
lation of 293 cells with leptin led to a significant increase in Stat3
phosphorylation at tyrosine 705 (Figure 1C). In contrast, when
challenged with tunicamycin, the leptin-induced Stat3 phos-
phorylation (Tyr705) was totally abolished (Figure 1C), indicating
that UPR signaling inhibits LepRB signaling at all steps. The
same experiments were repeated with dithiothreitol (DTT),
another commonly used ER stress-inducing agent, to prove
that tunicamycin-mediated blockade was not due to nonspecific
effects created by this agent (Figure 1D). Taken together, these
results suggest that activation of UPR signaling pathways blocks
leptin receptor signaling.
To exclude the possibility that LepRB-expressing 293 cells
become dysfunctional due to a possible toxicity generated by
tunicamycin, we investigated the insulin receptor (IR) activation
by stimulating the cells with insulin (100 nM) for 5 min after 5 hr
tunicamycin (3 mg/ml) treatment. During the 5 hr stimulation
(D) Analysis of LepRB signaling at the presence or absence of dithiothreitol (DTT) (1 mM). (Blots are representative of three independent experiments.)
(E) Insulin-stimulated insulin receptor (IR) activation in LepRB-expressing 293 cells after 5 hr DMSO or tunicamycin (3 mg/ml) stimulation. (Blots are representative
of two independent experiments.)
(F) LepRB staining in 5 hr DMSO or tunicamycin-treated LepRB-expressing 293 cells or in the nontransfected 293 cells. (Pictures are representative of three
independent experiments.)
(G) Binding of iodinated-leptin to LepRB after 5 hr of DMSO or tunicamycin stimulation. (Graph is representative of two independent experiments, and, in each of
the experiments, n = 3 for the given conditions.)
(H) A 26 gauge guide cannula was implanted into the third ventricle of the lean, 8-week-old C57BL/6 mice. Following a 7 day healing period, either vehicle or
tunicamycin (40 mg/ml, 2 ml) was infused to the third ventricle. At 12 hr following the infusion, hypothalamus was dissected. mRNA levels of spliced X box binding
protein 1 (XBP1s), (I) CCAAT/enhancer-binding protein-homologous protein (CHOP), and (J) endoplasmic reticulum-resident DNAJ 4 (ERDJ4) in the hypothal-
amus of vehicle- or tunicamycin-infused mice.
(K) Neuropeptide Y (NPY), (L) agouti-related peptide (AgRP), and (M) pro-opiomelanocortin (POMC) mRNA levels in the hypothalamus of the control and tunica-
mycin-infused mice.
(N) Third ventricles of the 8-week-old C57BL/6 mice were infused with vehicle or tunicamycin. Leptin (1 mg/kg) was administered intraperitoneally 5.5 hr after the
infusions, and phospho-Stat3 (Tyr705) and total Stat3 levels were determined within the hypothalamic protein samples.
(O) Food intake between 4 and 6 hr after tunicamycin infusion to the third ventricle. Graphs are representative of three independent experiments (n = 3 in each
experiment).
Error bars, ± SEM. p values are determined by Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001.
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ER Stress Causes Leptin ResistanceFigure 2. Improved ER Capacity Enhances Leptin Sensitivity
(A and B) Immunoblots of (A) XBP1s in the total cell lysates and (B) NH2 terminal of ATF6 (ATF6n) in nuclear extracts of the mouse embryonic fibroblasts (MEFs)
infected with adenovirus encoding either XBP1s (Ad-XBP1s) or ATF6n (Ad-ATF6n), respectively. (Both of the experiments in [A] and [B] were repeated indepen-
dently three times.)
(C) Relative activity of the endoplasmic reticulum stress element (ERSE)-driven luciferase reporter after LacZ, XBP1s, and ATF6n expression. (Graph is
representative of three independent experiments.)
(D and E) Relative expression levels of (D) ERDJ4 and (E) GRP78 after LacZ and XBP1s adenovirus infection. (Graph is representative of three to five independent
experiments in different cellular systems.)
(F) LepRB-expressing 293 cells were infected with the Ad-LacZ and Ad-XBP1s, and following overnight starvation, cells were stimulated with increasing doses of
tunicamycin (0.001, 0.01, 0.05, 0.1, 1 mg/ml) for 5 hr. Leptin was added to the medium at the last 45 min of the tunicamycin stimulation. Tyrosine phosphorylations
of LepRB, Jak2 and Stat3 (Tyr705) and their total protein levels were analyzed.
(G) The 293 cells expressing either LacZ or XBP1s were incubated with tunicamycin (0.05 mg/ml) in a time course manner up to 5 hr after an overnight starvation
and exposed to leptin (100 ng/ml) for additional 45 min. LepRB and Jak2 tyrosine phosphorylations were investigated after immunoprecipitation, and Stat3
(Tyr705) phosphorylation has been examined with direct immunoblotting in whole-cell lysates.
(H) Following infection with Ad-ATF6n, 293 cells were incubated in 1% FBS containing medium for 14 hr and then stimulated with increasing doses of tunicamycin
(0.001, 0.01, 0.05, 0.1, and 1 mg/ml) for 5 hr. Cells were given leptin (100 ng/ml) stimulation at the last 45 min of the tunicamycin incubation. LepRB and Jak2
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ER Stress Causes Leptin Resistanceperiod, insulin-stimulated IR tyrosine phosphorylation did not
change, which supports the observation that LepRB-expressing
293 cells are functional during the experimental time frame that
we used (Figure 1E).
Considering the fact that LepRB is folded in the ER, we inves-
tigated whether ER stress blocks leptin receptor translocation to
the membrane from the ER and whether this could be a reason
for the blockade of leptin signaling. We stimulated the 293 cells
with tunicamycin for 5 hr (3 mg/ml) and analyzed leptin receptor
levels in the plasma membrane by immunofluorescence staining.
As shown in Figure 1F, LepRB folding is still preserved, and its
translocation to the membrane is not decreased in ER stress
conditions. Next, we performed leptin-binding assays in DMSO
and tunicamycin-treated cells to exclude the possibility of
a defect in binding of leptin to LepRB. Surprisingly, leptin binding
to LepRB significantly increased in ER stress conditions
(Figure 1G).
ER Stress Creates Leptin Resistance in the Brain
of Lean Mice
To investigate whether leptin action could also be blocked by
directly inducing ER stress in brains of lean mice, we inserted
a guide cannula to the third ventricle and infused tunicamycin
and vehicle as control. mRNA levels of ER-stress-responsive
genes such as the spliced form of X box binding protein 1
(XBP1s), CCAAT/enhancer-binding protein-homologous protein
(CHOP), and endoplasmic reticulum resident DNAJ 4 (ERDJ4)
were significantly upregulated in hypothalami of tunicamycin-
infused mice (Figures 1H, 1I, and 1J), indicating that ER stress
can be induced in the hypothalamus of lean mice by tunicamycin
infusion.
Next, we investigated the expression patterns of leptin resis-
tance markers such as neuropeptide Y (NPY) and agouti-related
peptide (AgRP) in the vehicle- and tunicamycin-infused mice.
Induction of ER stress in the brain of the lean mice led to a signif-
icant increase in the mRNA levels of NPY and AgRP, indicating
a leptin-resistant state (Figures 1K and 1L). The POMC mRNA
levels did not show any significant difference in the tunicamy-
cin-infused hypothalami (Figure 1M). In addition, to exclude the
possibility that tunicamycin infusion leads to a decay in mRNA
degradation of NPY and AgRP due to a possible toxic effect,
we analyzed mRNA levels of IR and insulin receptor substrate
1 (IRS1) (Figures S1A and S1B).
To assess whether activation of UPR signaling would create
leptin resistance and block the leptin-stimulated Stat3 activation
in the hypothalamus, leptin (1 mg/kg/day) was intraperitoneally
administered 5.5 hr after tunicamycin infusion. IP administration
of leptin led to a marked increase in Stat3 phosphorylation in the
hypothalamus (Figure 1N). In contrast, administration of tunica-
mycin to the third ventricle and creation of ER stress, in complete
accordance with our data obtained from 293 cells, blocked acti-
vation of Stat3 in the hypothalamus (Figure 1N). Furthermore,
infusion of tunicamycin to the third ventricle significantly
increased acute food intake (Figure 1O).
Improvement of ER Function Enhances Leptin Signaling
XBP1s is one of the master regulators of ER folding capacity
(Ron and Walter, 2007; Schroder and Kaufman, 2005). To deter-
mine whether exogenous expression of XBP1s and a conse-
quent increase in ER function would enhance leptin receptor
signaling, we generated an XBP1s-encoding adenovirus (Ad-
XBP1s) and also a LacZ-expressing adenovirus (Ad-LacZ) as
a control. Infection of mouse embryonic fibroblasts (MEFs)
with Ad-XBP1s increased the protein level of XBP1s
(Figure 2A), upregulated ERSE promoter activity (Figure 2C),
and increased the ERDJ4 mRNA levels (Figure 2D). After
showing that newly generated Ad-XBP1s is functional, we
subsequently overexpressed the XBP1s in the LepRB-express-
ing 293 cells and performed two sets of experiments. First, we
stimulated the 293 cells with increasing doses of tunicamycin
(0.001, 0.01, 0.05, 0.1, and 1 mg/ml) for 5 hr and analyzed
leptin-stimulated LepRB activation. In Ad-LacZ infected
cells, LepRB activation was blocked at tunicamycin doses of
0.01 mg/ml and higher (Figure 2F). In contrast, infection with
Ad-XBP1s led to a marked increase in leptin-stimulated LepRB
tyrosine phosphorylation even at the basal state, without altering
the LepRB activation at the absence of leptin. XBP1s overex-
pression increased the resistance of cells to the inhibitory effect
of tunicamycin of up to 0.05 mg/ml. Even at the doses of 0.1 and
1 mg/ml of tunicamycin, leptin-stimulated activation of LepRB in
XBP1s overexpressing cells was higher than the LacZ-express-
ing cells in the absence of tunicamycin (Figure 2F). Both 0.01
and 0.05 mg/ml of tunicamycin concentration significantly
induces ER stress and upregulates CHOP expression in the
293 cells (Figure S1C).
In the second set of experiments, we performed time course
tunicamycin stimulation to determine at which time points the
leptin receptor activity begins to decay. When Ad-LacZ infected
293 cells were treated with 0.05 mg/ml dose of tunicamycin,
leptin-stimulated LepRB and Jak2 activation, as well as Stat3
tyrosine phosphorylation, were blocked within 2 hr. In contrast,
overexpression of XBP1s prevented the ER stress-mediated
blockade of LepRB, Jak2, and Stat3 tyrosine phosphorylations
throughout the experimental period (Figure 2G).
If the increased leptin sensitivity after XBP1s expression was
due to enhanced ER capacity, then another means of upregulat-
ing ER capacity should similarly enhance LepRB activation. Acti-
vating transcription factor 6a (ATF6) belongs to the bZIP
transcription factor family and is also a fundamental regulator
of ER adaptive capacity (Ron and Walter, 2007). Accordingly,
we constructed adenovirus expressing the NH2-terminal (1–
373 aa) of ATF6a (Ad-ATF6n). Following the characterization of
the adenovirus (Figures 2C and 2E), we infected the LepRB-
expressing 293 cells with Ad-ATF6n and performed dose curve
immunoprecipitates were immunoblotted with a phosphotyrosine antibody, and Stat3 tyrosine phosphorylation was analyzed with a phosphospecific antibody
raised against tyrosine 705.
(I) LacZ and ATF6n-infected 293 cells were taken to time course (1, 2, 3, 4, and 5 hr) tunicamycin (0.05 mg/ml) stimulation and stimulated with leptin (100 ng/ml) for
45 min. Subsequently, LepRB signaling parameters were analyzed.
Error bars, ± SEM. p values are determined by Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001. Each experiment in (F–I) was repeated three times.
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ER Stress Causes Leptin Resistanceand time course tunicamycin treatment. Similar to the XBP1s,
expression of ATF6n significantly upregulated the leptin-stimu-
lated LepRB tyrosine phosphorylations at the basal conditions
(Figure 2H). Similar to the results obtained from XBP1s gain-
of-function experiments, ATF6n increased the resistance of
293 cells to tunicamycin and blocked the ER stress-mediated
inhibition of LepRB signaling (Figures 2H and 2I).
ER Capacity of the Brain Links Obesity to Leptin
Resistance
If the conditions that lead to development of obesity create
perturbations in ER system and activate UPR signaling path-
ways, and if this signaling network plays a dominant role in the
development of leptin resistance, it would be expected that
a brain with a lower ER capacity, when exposed to the conditions
that create obesity, will develop an earlier and higher degree of
leptin resistance that will ultimately trigger the development of
a more severe form of obesity. To test this hypothesis in vivo,
we created neuron-specific XBP1 knockout mice (XNKO) by
crossing the XBP1flox/flox mice with mice expressing Cre recom-
binase under the control of the nestin gene promoter. As previ-
ously reported (Hetz et al., 2008), XNKO mice are born in
a Mendelian ratio and do not have any obvious phenotypic
abnormality. Figure 3A shows the PCR analysis of floxed and
Cre alleles of the XNKO and XBP1flox/flox mice. To demonstrate
that XBP1 levels were reduced in the CNS and particularly in
the hypothalamus of the XNKOmice, we have taken two different
approaches. First, we exposed isolated embryonic cortical
neurons to a high dose of tunicamycin (20 mg/ml) for a period
of 6 hr. Exposure of XBP1flox/flox neurons to tunicamycin resulted
in robust upregulation of the XBP1s protein levels (Figure 3B).
However, this response is completely abolished in the neurons
isolated from XNKO embryos, indicating that deletion of XBP1
is complete. Furthermore, we stimulated XBP1flox/flox and
XNKO hypothalamic explants with tunicamycin (20 mg/ml) for
6 hr and demonstrated that there is a severe reduction in the
protein levels of XBP1s in the XNKO hypothalamus (Figure 3C).
After showing that XBP1 can be significantly reduced in
XBP1flox/flox/NesCre+/ mice, we first analyzed the phenotype
of the XBP1flox/flox and XNKO mice under normal diet feeding.
The body weight of XNKO mice is slightly lower than the
XBP1flox/flox mice under normal diet feeding conditions
(Figure S2A). Blood glucose levels and leptin levels were similar
during the experimental period for up to 12 weeks (Figures S2B
and S2C). Performance of insulin (ITT) and glucose (GTT) toler-
ance tests showed that glucose homeostasis can be maintained
under normal range in the XNKO mice under normal diet feeding
(Figures S2D and S2E). Finally, we investigated the hypothalamic
leptin receptor signaling by administering intraperitoneal leptin
(1 mg/kg). Leptin-stimulated tyrosine phosphorylation of Stat3
does not show any difference between the XNKO and
XBP1flox/flox control mice (Figure S2F), indicating that leptin
action is preserved in the XNKO mice under normal diet feeding.
Next, we placed XNKO and XBP1flox/flox mice on high-fat diet
at the age of 3.5 weeks, immediately after weaning. When chal-
lenged with HFD, XNKO mice gained more weight beginning at
the second week and reached significantly higher levels of
body weight by the fourth week (26.68 ± 0.64 g versus 23.53 ±
0.53, XNKO versus XBP1flox/flox, p = 0.002). XNKO mice
continued to gain weight at a more rapid rate than the control
mice throughout the experimental period (Figure 3D).
Soon after initiation of HFD, leptin levels sharply increased in
XNKO mice and reached 83.92 ± 8.2 ng/ml by the fourth week,
corresponding to a 20-fold upregulation over the basal (pre-
HFD) level (Figure 3E). The leptin levels continued to increase
in XNKO mice during the course of the experiment and reached
up to 50-fold higher levels (206.4 ± 17.56 ng/ml) by week 12 of
HFD (Figure 3E). HFD feeding led to a much smaller increase in
the leptin levels of the control XBP1flox/flox mice (Figure 3E). Addi-
tionally, measurement of 24 hr food intake at the twelfth week of
HFD demonstrated that the XNKO group consumed more food
than the XBP1flox/flox group (2.51 ± 0.09 g versus 2.08 ± 0.07 g,
XNKO versus XBP1flox/flox, p < 0.01) (Figure 3F). Performance
of dual-energy X-ray absorptiometry (DEXA) scan has shown
that the XNKO mice has significantly lower lean mass (p <
0.001) but a higher total fat amount when compared with the
XBP1flox/flox mice (p < 0.001) (Figures 3G, 3H, and 3I). We per-
formed a regression analysis to estimate the fat percentage-lep-
tin level relationship in XBP1flox/flox mice, whose fat ranged
between 15% and 20%. For XNKO mice, with fat percentage
ranging between 45% and 50%, the regression would predict
leptin levels around 60 ng/ml. Nonetheless, all five XNKO levels
fell between 100 and 250 ng/ml, well above the prediction line
(Figure 3J).
Figure 3. Deficiency of XBP1 in Neurons Increases Susceptibility to Develop Leptin Resistance
XBP1flox/flox mice on C57BL/6 background were intercrossed with the C57BL/6 mice that express the Cre recombinase under the nestin promoter.
(A) PCR analysis of the floxed and Cre alleles for genotyping.
(B) Cortical neurons were isolated from XBP1flox/flox and XNKO embryos at embryonic day15–16. Following an overnight culture, neurons were stimulated with
either DMSO or tunicamycin (20 mg/ml) for 6 hr, and XBP1s protein levels were analyzed with immunoblotting.
(C) Hypothalami were removed from the XNKO and XBP1flox/flox mice, dissected into small pieces, and incubated in basal neuron culture medium. Following 2 hr
of incubation, tunicamycin (20 mg/ml) was added to the medium, and hypothalamic explants were treated with tunicamycin for 6 hr. XBP1s protein levels were
analyzed with immunoblotting.
(D and E) (D) Body weight (g) and (E) plasma leptin (ng/ml) levels of XBP1flox/flox and XNKO mice during the course of high-fat diet feeding.
(F–J) (F) Regression analysis of leptin levels and fat percentage in the XBP1flox/flox and XNKO mice and (G) 24 hr food intake (g) at the twelfth week of HFD feeding.
Dexa scan analysis of (H) lean mass (g), (I) total fat amount (g), and (J) fat percentage at the twelfth week of HFD feeding. Metabolic cage analysis was performed
on XBP1flox/flox and XNKO mice at the eleventh week of HFD feeding.
(K–P) (K) O2 consumption (ml/kg/hr), (L) CO2 production (ml/kg/hr), (M) respiratory exchange ratio (VCO2/VO2), (N) x axis ambulatory activity, (O) heat generation
(kcal/hr), and (P) blood glucose levels (mg/dl) at the twelfth week of HFD.
(Q) Hypothalamic PERK phosphorylation (Thr 980) in the XBP1flox/flox and XNKO mice at the thirteenth week of HFD.
(R) Leptin (IP, 1 mg/kg)-stimulated phosphorylation of Stat3 (Tyr705) in the XBP1flox/flox and XNKO mice at the thirteenth week of HFD.
n = 6 for XNKO group, and n = 11 for XBP1flox/flox group. The phenotype that has been observed inXNKOmice has been reproduced in two additional independent
cohorts. Error bars, ± SEM. p values are determined by Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4. PBA Increases Leptin Sensitivity in the ob/ob Mice
(A) The 9-week-old lean WT and ob/ob mice were orally treated with either 4-phenyl butyrate (PBA) (1 g/kg/day) or vehicle (VEH) for 26 days, and PERK (Thr980)
phosphorylation is examined in the hypothalamus extracts with direct immunoblotting.
(B and C) mRNA levels of (B) XBP1s and (C) CHOP in the hypothalamus of lean and ob/ob mice after 6 hr of fasting.
(D) The 10-week-old WT lean and ob/ob mice were intraperitoneally injected with leptin (0.1 mg/kg) after 6 hr starvation. Hypothalami were removed 30 min after
the injections, and pStat3Tyr705 and total Stat3 levels were examined. (Experiments were repeated in two independent cohorts.) The 9-week-old lean WT and
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and XNKO groups. Parallel to the obesity phenotype, XNKO
mice consume significantly less O2 and produce a significantly
lower amount of CO2 (Figures 3K and 3L). Although there was
a slight decrease in the respiratory exchange ratio in XNKO
mice, this parameter was not statistically different (Figure 3M).
In addition, XNKO mice are significantly less active in the dark
cycle and over the total recording time (Figure 3N). Heat produc-
tion does not differ between the groups (Figure 3O).
Insulin levels were also significantly upregulated during the
course of HFD feeding (Figure S3A), and 6 hr fasted blood
glucose of XNKO mice was significantly higher than control
mice at the twelfth week of HFD (Figure 3P). Additionally, we
performed GTT and ITT at weeks 10 and 12, respectively.
XNKO mice were significantly more glucose intolerant than
XBP1flox/flox control mice (Figure S3B). The hypoglycemic
response to insulin was significantly blunted in the XNKO mice
during the ITT (Figures S3C, S3D, and S3E). Furthermore, we
investigated the response of XBP1flox(/)/NesCre(/),
XBP1flox(+/+)/NesCre(/), and XBP1flox(/)/NesCre(+/) mice to
high-fat diet feeding to examine whether there is any difference
between these groups. During the 12 weeks of HFD feeding,
body weight and other parameters did not show any significant
alterations between the groups (Figure S4).
If development of a more severe form of obesity in XNKO mice
is due to a higher level of ER stress and a consequent decrease in
leptin signaling in the hypothalamus, then it would be expected
that XNKO mice will have more ER stress and will be less sensi-
tive to acute injection of leptin. To address these questions, we
first analyzed the PERK phosphorylation in the hypothalamus
of the XNKO and XBP1flox/flox mice after 12 weeks of HFD
feeding. As shown in Figure 3Q, PERK phosphorylation
(Thr980) is markedly upregulated in the hypothalamus of the
XNKO mice, and leptin-stimulated Stat3Tyr705 phosphorylation
is significantly blunted in the XNKO mice (Figure 3R).
As a final step in characterization of the XNKO mice, we
analyzed the pancreas histology by either hematoxylin and eosin
(H&E) or insulin/glucagon immunofluorescence stainings. There
is a marked hyperplasia in the islets of the XNKO mice (Fig-
ure S5A). In addition, PERK phosphorylation is both increased
in the liver and adipose tissues of theXNKOmice when compared
with the XBP1flox/flox control mice Figures S5B and S5C).
Collectively, our results support the hypothesis that ER
capacity of the brain is a crucial regulator of body weight, leptin
sensitivity, and, thus, metabolic homeostasis.
Chemical Chaperones Are Leptin Sensitizers
Chemical chaperones constitute a group of low-molecular-
weight compounds that have been shown to increase ER
function and decrease the accumulation and aggregation of
misfolded proteins in the ER lumen and, consequently, reduce
ER stress (Perlmutter, 2002). 4-phenyl butyrate (PBA) and taur-
oursodeoxycholic acid (TUDCA) are U.S. Food and Drug Admin-
istration (FDA)-approved chemical chaperones and have high
safety profile in humans (Chen et al., 1997; Maestri et al.,
1996). Recent evidence suggests that PBA and TUDCA relieve
ER stress in liver and adipose tissues, enhance insulin sensitivity,
and maintain euglycemia in a mouse model of severe obesity
and type 2 diabetes (ob/ob) (Ozcan et al., 2006). PBA and TUDCA
also exert chaperone activity within the CNS (Inden et al., 2007;
Petri et al., 2006; Sola et al., 2003). Considering these findings,
we asked whether we could reverse ER stress in the hypothal-
amus of the obese mice by chemical chaperone treatment and,
consequently, use this strategy to increase leptin sensitivity.
Ob/obmice are known to respond to high levels of leptin. If our
view, which implies that obesity conditions or the conditions that
are leading to obesity create ER stress and, consequently, leptin
resistance, is a valid one, then ER stress should also be upregu-
lated in the hypothalamus of the ob/ob mice, and this should
create at least some degree of leptin resistance, which, in turn,
should be ameliorated by the blockade of UPR signaling. Indeed,
the phosphorylation of PERK (Thr980) is increased in the hypo-
thalamus of the ob/ob mice, indicating that ER stress is
increased when compared to lean counterparts (Figure 4A).
Furthermore, administration of PBA significantly reduced PERK
phosphorylation, constituting evidence that hypothalamic ER
stress can be modulated with PBA (Figure 4A). In addition, we
analyzed mRNA levels of XBP1s and CHOP in the hypothalamus
of lean and ob/obmice after 6 hr fasting during the light cycle and
demonstrated that both of the markers are significantly upregu-
lated in the hypothalamus of the ob/ob mice when compared
with the lean counterparts (Figures 4B and 4C).
After showing that UPR signaling is activated in the hypothal-
amus of the ob/obmice, we sought to determine whether there is
any difference in response of the ob/ob mice to leptin in terms of
activating the LepRB signaling cascade in the hypothalamus. We
intraperitoneally injected low doses (compared to the commonly
used doses) of leptin (0.1 mg/kg) to aged-matched male WT and
ob/ob mice at 6 hr fasting and extracted the hypothalamus
30 min after the injections. As shown in Figure 4D, WT lean
mice responded well to this dose of leptin by increasing the
Stat3Tyr705 phosphorylation in the hypothalamus. In contrast,
this response is completely absent in the ob/ob mice, indicating
that ob/obmice have some degree of defect in activating the lep-
tin-signaling pathway when compared with the WT mice
(Figure 4D).
To test whether reduction of ER stress will increase leptin
sensitivity of the ob/ob mice, we orally administered PBA or
vehicle for 10 days as a pretreatment. Following this period,
daily leptin injections (IP) were given at doses ranging from
ob/ob mice were orally treated with PBA (1 g/kg/day) for 10 days. Following the pretreatment period, leptin-deficient ob/ob mice were either administered with
VEH or with different doses of leptin through the intraperitoneal route.
(E–G) The effect of VEH or PBA administration on (E) body weight (g), (F) percent decrease in body weight, and (G) 24 hr food intake (n = 3 for VEH, and n = 4 for
PBA-treated group).
(H–J) Effect of 5 mg/kg/day leptin administration on (H) body weight, (I) percent decrease in body weight, and (J) 24 hr food intake in VEH- or PBA-treated ob/ob
mice (n = 3 for VEH, and n = 4 for PBA-treated group).
(K–P) Analysis of the same parameters (body weight, percent decrease in body weight, and 24 hr food intake) in (K)–(M) 1 mg/kg/day and (N)–(P) 0.1 mg/kg/day
leptin-treated mice (n = 3 for VEH, and n = 4 for PBA-treated group).
Data presented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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ER Stress Causes Leptin Resistance0.01 mg/kg/day to 5 mg/kg/day. Oral PBA administration did not
affect the body weight or food consumption as compared to the
vehicle-treated group alone (Figures 4E, 4F, and 4G). In the
vehicle-treated group, the highest dose of leptin (5 mg/kg/day)
significantly inhibited food intake (Figure 4H) and, during 16
days of treatment, reduced body weight from 56 ± 1.16 g to
41.13 ± 2.35 g (Figure 4F), a 27.33% decrease in the body weight
(Figure 4G). However, in the PBA-treated group, the same (5 mg/
kg/day) dose of leptin further inhibited food intake and reduced
body weight from 54.30 ± 1.40 g to 30.30 ± 0.82 g (Figure 4F),
corresponding to a 44.73% ± 2.55% decrease from the initial
weight. This reduction was significantly greater than that
seen in the vehicle-treated group (44.73% ± 2.55% versus
27.33% ± 2.65%, PBA versus vehicle, p < 0.0001).
Furthermore, PBA pretreatment dramatically increased the
sensitivity ofob/obmice to the anorexigenic effect of lower doses
of leptin (1 mg/kg/day or 0.1 mg/kg/day). Following vehicle
pretreatment, 1 mg/kg/day leptin treatment led to a significant
decrease in body weight, albeit to a lesser extent than that seen
at 5 mg/kg/day, by reducing the initial weight from 57.10 ±
0.58 g to 46.61 ± 0.52 g (17.73% reduction in body weight)
(Figure 4I). However, following PBA pretreatment, the same
1 mg/kg/day leptin dose reduced body weight from 52.93 ±
0.26 g to 34.21 ± 1.74 g, corresponding to a 35.21% decrease
in body weight (p < 0.001) (Figure 4I). At the lowest dose
(0.1 mg/kg/day), leptin alone did not significantly reduce the body
weight (Figure 4I). However, when ob/ob mice were pretreated
with PBA, 0.1 mg/kg/day leptin decreased body weight from
53.82 ± 0.4 g to 44.77 ± 1.67 g, corresponding to a 16.77%
decrease in body weight, which is commensurate with the level
created by vehicle plus 1 mg/kg/day leptin, a 10-fold higher
dose (Figure 4J). We also analyzed the blood glucose levels of
the vehicle, leptin (5 mg/kg/day), PBA, and PBA + leptin-treated
(5 mg/kg/day) ob/ob mice. When the ob/ob mice were treated
with PBA and leptin together, blood glucose levels decreased to
91 ± 15 mg/dl, which is significantly lower than the PBA and leptin
treatments alone. In addition, we treated the male and age-
matched lean C57BL/6 mice with the same combination of leptin
dosesand PBA.Asshown inFigureS6, PBA itself did not decrease
the body weight and food consumption (Figures S6A–S6l).
To investigate whether the effect created by PBA and leptin
combinatory treatment is solely mediated through the LepRB
and is not due to a nonspecific effect, we performed the same
experiment in the db/db mouse model, which lacks the leptin
receptor. During the 16 days of experimental period, vehicle
and PBA-treated groups significantly gained weight (Figures
5A and 5B), and there was no difference in the amount of food
consumption between the vehicle and PBA-treated db/db
mice. However, blood glucose levels of PBA-treated db/db
mice were reduced to a significantly lower level, indicating that
PBA is also capable of increasing insulin sensitivity in the db/
db obesity model (Figure 5D). As expected, leptin treatment
alone did not decrease the food intake and body weight of the
db/db mice (Figures 5A, 5B, and 5C). Coadministration of leptin
with PBA did not also change any of the parameters (increase in
body weight, food consumption) (Figures 5A, 5B, and 5C), indi-
cating that the leptin-sensitizing effect of PBA is solely mediated
by the leptin receptor, but not through other possible signaling
pathways, including the insulin receptor signaling.
Obesity owing to a high-fat diet is fundamentally different from
that seen in ob/ob mice in that it occurs in the face of high leptin
levels. To determine whether PBA also sensitizes HFD-fed obese
mice to leptin, mice that were kept on HFD for 25 weeks were
pretreated with vehicle or PBA for 10 days and then given leptin
treatment (5 mg/kg/day). Leptin administration to the vehicle-
treated group led to an acute weight loss, which was rapidly re-
gained (Figure 6A). By the end of treatment period, leptin created
a slight but significant change in the body weight in the vehicle-
treated group by reducing it from 42.42 ± 0.27 g to 40.78 ± 0.55 g
(3.8% ± 0.9% decrease in body weight) (Figures 6A and 6B).
However, PBA pretreatment increased the efficacy of leptin by
significantly decreasing the daily food intake (Figure 6C) and
leading to a 15.72% ± 2.85% reduction in body weight by
reducing the initial weight from 41.18 ± 0.49 g to 34.71 ± 0.69 g
(Figures 6A and 6B). During the course of the experiment, we
placed the vehicle and PBA-treated groups in metabolic cages
to investigate metabolic homeostasis in detail. As shown in
Figure 6D, PBA treatment significantly increased leptin-stimu-
lated O2 consumption. It also led to an increase in CO2 produc-
tion (Figure 6E), but not at a significant level. At the dark cycle
and in total recording time, activity of the PBA + leptin-treated
mice significantly increased when compared with the leptin-
treated group alone (Figure 6F). The respiratory exchange ratio
in the PBA-treated group was significantly reduced in the dark
cycle and also slightly in the light cycle (Figure 6G). In addition,
heat production also shows slight upregulation in the PBA + lep-
tin-treated mice (Figure 6H). Following the metabolic cage anal-
ysis, we performed DEXA scan to analyze whole-body fat
Figure 5. PBA and Leptin Coadministration in db/db Mouse Model
The 6-week-old db/db mice were orally treated with either PBA (1 g/kg/day) or
VEH for 4 days. Following the pretreatment period, leptin-receptor-deficient
db/db mice were either administered with VEH or leptin (1 mg/kg) through
intraperitoneal route for 16 days.
(A–C) (A) Body weight (g), (B) percent increase in body weight, and (C) 24 hr
food intake.
(D) Blood glucose (mg/dl) levels of the groups (n = 5 in each group).
Error bars, ± SEM. p values are determined by Student’s t test. *p < 0.05, **p <
0.01, ***p < 0.001.
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(Figure 6I). However, fat percentage and total fat amount is
significantly reduced in PBA + L group (Figures 6J and 6K).
To investigate whether PBA treatment reduces the ER stress,
we analyzed the PERK phosphorylation in the HFD-fed mice,
which were either treated with VEH or PBA for 16 days. PBA
treatment alone did not reduce the body weight and food intake
when compared with the VEH-treated group (Figure S7).
However, as shown in Figure 6I, PBA treatment led to a marked
decrease in PERK phosphorylation in the hypothalamus of the
HFD-fed obese mice, indicating that ER stress is reduced. To
investigate whether leptin-stimulated activation of LepRB
signaling is increased in the hypothalamus of the PBA-treated,
HFD-fed obese mice, we intraperitoneally injected leptin (0.75
mg/kg) following a 6 hr fast and analyzed the Stat3Tyr705
phosphorylation in the hypothalamus extracts of VEH and
PBA-treated mice. PBA treatment led to a marked upregulation
in leptin-stimulated Stat3Tyr705 phosphorylation (Figure 6M).
Treatment of ND-fed lean mice with PBA did not cause a higher
activation of Stat3Tyr705 when compared with the VEH-treated
group (Figure 6N). Collectively, these data provide evidence
that PBA is effective in genetic and diet-induced obesity models
as a leptin sensitizing agent.
Leptin resistance in obesity arises due to both impairment of
leptin action in the hypothalamus and defects in the transport
of leptin in the blood brain barrier (Banks, 2003; Flier, 2004). To
investigate whether PBA treatment caused a generalized
increase in the blood brain barrier permeability, we treated the
HFD-fed WT male mice with PBA for 12 days and then injected
with the retrogradely transported marker substance Fluoro-
gold (IP, 15 mg/kg). As shown in Figure S8, there is Fluoro-
gold immunostaining in the median eminence (ME) of both VEH
and the PBA-treated mice. Reactivity against the Fluoro-gold is
not different between the vehicle and PBA-treated groups. Flu-
oro-gold-labeled neurons should be present in the areas like
ventromedial hypothalamus (VMH), dorsomedial hypothalamus
(DMH), and lateral hypothalamic area (LHA) if the BBB perme-
ability is perturbed. However, we did not observe any Fluoro-
gold-labeled neurons in these areas, indicating that BBB perme-
ability is not increased with the use of PBA (Figure S8).
If the postulate that reduction of ER stress in the hypothalamus
increases leptin sensitivity is true, chemical chaperones other
than PBA should also create the same effect and sensitize the
obese mice to leptin. TUDCA is a hydrophilic bile acid, which
has a completely different structure than PBA but has chemical
chaperone activity in common (Ozcan et al., 2006). First, we
investigated whether TUDCA can reduce ER stress in the hypo-
thalamus of the ob/ob mice. For this purpose, we treated ob/ob
mice either with vehicle or TUDCA (150 mg/kg/day) for a period
of 21 days and analyzed the hypothalamic PERK phosphoryla-
tion. TUDCA treatment, similar to PBA, downregulated the
PERK activity, indicating that TUDCA is also capable of reducing
ER stress in the hypothalamus of the ob/ob mice. Taking this
data into account, we asked whether TUDCA might also act as
a leptin-sensitizing agent. To address this question, we first pre-
treated the ob/ob mice with TUDCA (150 mg/kg/day) for 5 days
and subsequently initiated leptin (1 mg/kg) treatment. As shown
in Figure 7B, neither TUDCA nor the vehicle alone increased the
body weight of the ob/ob mice. Leptin treatment decreased thebody weight from 50.50 ± 0.55 g to 43.75 ± 0.22 g, which corre-
sponds to a 9.27% ± 1.34% reduction from the initial value.
Body weight of the ob/ob mice decreased further with leptin
and TUDCA cotreatment and reached 34.39 ± 1.30 g from
50.55 ± 1.14 g (25.14% ± 1.83% decrease, Lep versus TUD +
Lep, p < 0.001). In addition, we investigated the daily food intake
and showed that administration of leptin together with TUDCA
significantly augments the appetite-suppressing effect of leptin
(Figure 7D). Administration of TUDCA lowered the blood glucose
levels, and addition of leptin to the treatment slightly reduced the
blood glucose levels further (Figure 7E). Furthermore, to investi-
gate the metabolic homeostasis in greater detail, we placed the
mice in metabolic cages. As shown in Figures 7F and 7G, co-
treatment with TUDCA and leptin increased CO2 production
and O2 consumption. The respiratory exchange rate in the dark
cycle showed slight downregulation, but not at a significant level
(Figure 7H). The total activity of the TUDCA- and leptin-cotreated
group was significantly higher than the leptin-only-treated group
(Figure 7I). Heat generation was the same between the groups
(Figure 7J). Next, we analyzed the whole-body fat composition
by DEXA scan. TUDCA and leptin cotreatment led to a severe
reduction in total fat amount and whole-body fat percentage,
which are both significantly lower than the leptin-treated group
alone (Figures 7K and 7L). Finally, analysis of lean mass has
shown that none of the treatments lead to a significant change
in this parameter (Figure 7M). We additionally investigated the
effect of TUDCA and leptin cotreatment on C57BL/6 WT-lean
mice (Figures S9A, S9B, and S9C).
We next tested the efficacy of TUDCA as a leptin sensitizer in
the HFD-induced obesity model. In this experiment, we used
35-week-old and C57BL/6 WT mice, which were kept on HFD
feeding for 32 weeks. We divided the mice into two groups for
TUDCA and TUDCA-leptin cotreatment. Body weight of the
mice in this cohort was between 35 and 52 g. We specifically
chose the mice with the highest body weight for the TUDCA
and leptin cotreatment group to investigate whether leptin will
become effective in these severely obese mice when adminis-
tered along with the TUDCA. The initial body weight of the
TUDCA group was 38.33 ± 1.16 g, and the TUDCA + leptin group
was 48.46 ± 1.82 g (Figure 7N). Following an initial 5 days accli-
mation period, mice were treated with TUDCA (150 mg/kg/day)
for 4 days, and, subsequently, either vehicle or TUDCA treatment
was started. Following the acclimation, TUDCA pretreatment
was started, and following the 5 day pretreatment, vehicle and
leptin (1 mg/kg/day) administration were initiated. TUDCA alone
led to a significant decrease in body weight by reducing the initial
weight from 36.16 ± 0.99 g to 32.61 ± 0.65 during the 16 days of
treatment period (Figures 7N and 7O). Incapability of TUDCA in
lowering the body weight of ob/ob (Figure 7B) or WT lean mice
(Figure S9A) strongly indicates that TUDCA increases leptin
sensitivity in such a way that endogenous high levels of leptin
become effective. Indeed, in our experience, TUDCA acts as
a much more powerful chemical chaperone when compared to
PBA, as doses of TUDCA necessary for reducing ER stress in
cellular systems (Ozcan et al., 2006) or as a leptin-sensitizing
agent are much lower than for PBA. For example, administration
of 50 mg/kg/day TUDCA to the ob/ob mice also significantly
sensitizes this model to leptin. When administered with 50 mg/
kg/day TUDCA, leptin’s body-weight-reducing effect isCell Metabolism 9, 35–51, January 7, 2009 ª2009 Elsevier Inc. 45
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C57BL/6 mice that were kept on high-fat diet feeding for 25 weeks were either treated with vehicle or PBA (1 g/kg/day) for 10 days. Following the pretreatment
period, mice were given daily leptin (5 mg/kg/day, IP) treatment.
(A–H) (A) Body weight (g), (B) percent of decrease in the body weight, and (C) 24 hr food intake (g) during the 30 days of leptin administration. Metabolic cage
analysis was performed after 25 days of treatment. (D) O2 consumption (ml/kg/hr), (E) CO2 production (ml/kg/hr), (F) x axis ambulatory activity, (G) respiratory
exchange ratio (VCO2/VO2), (H) heat generation (kcal/hr).
(I–K) Dexa scan analysis of (I) lean body mass (g), (J) fat percentage, and (K) total fat amount (g). C57BL6 mice were fed a HFD for a period of 25 weeks and then
either treated with PBA (1 g/kg) or VEH for 16 days.
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kg/day] + Lep, 9.27% ± 1.34% versus 15% ± 0.87%, p < 0.001).
The limited efficacy of PBA could be the underlying reason
for PBA’s inability alone to decrease the body weight in the
HFD-induced obesity model, since the leptin amount in the
circulation may not be enough to overcome the remaining leptin
resistance after the PBA treatment. Indeed, the leptin levels are
significantly reduced after TUDCA, but not after 4-PBA treatment
(Figure S10). Finally, coadministration of TUDCA and leptin
generated a robust effect and reduced the body weight of
HFD-fed obese mice from 45.19 ± 1.95 g to 35.61 ± 1.93 g, which
is equal to an 18.88% decrease (Figures 7N and 7O) (TUD versus
TUD + Lep, p < 0.001).
When our data is taken together, we believe that we can safely
postulate that chemical chaperones or the agents, which have
the ability to decrease ER stress, are leptin sensitizers. However,
it is in the meantime possible that unknown effects of PBA and
TUDCA other than decreasing ER stress may also contribute to
increased leptin sensitivity.
DISCUSSION
Obesity is an escalating problem that constitutes a major threat
to global human health. An alarming increase in the incidence of
obesity among the pediatric population casts the disease into
a new and more concerning dimension (Narayan et al., 2003;
Rocchini, 2002). Although urgent therapeutic interventions are
needed, effective therapeutic modalities to cure or prevent the
development of obesity are limited.
In the present work, we have demonstrated that obesity
creates ER stress and initiates the unfolded protein response
signaling pathways in the hypothalamus, which, in turn, leads
to inhibition of leptin receptor signaling and creation of leptin
resistance. Our observations in the cellular systems exclude
the possibility of a defect in LepRB folding in ER stress condi-
tions, since translocation of LepRB to the membrane is not
altered. It is surprising that binding of leptin to LepRB increases
when cells are experiencing ER stress. This could be due to
decreased LepRB internalization after binding of leptin in ER
stress conditions. In addition, acute generation of ER stress in
the hypothalamus of lean mice creates a phenotype similar to
that seen in the brain of the obese mice. Tunicamycin infusion
to the third ventricle increases AgRP and NPY levels and
completely blocks leptin-stimulated Stat3 activation. In a heterol-
ogous cell system, enhancement of ER capacity leads to a robust
leptin-stimulated LepRB activation, suggesting that ER capacity
is directly related to the leptin sensitivity. Providing additional
support to this hypothesis, we demonstrated that neuronal dele-
tion of XBP1 and a consequent reduction in ER function creates
severe ER stress in the hypothalamus, blocks leptin action, and
generates leptin resistance in mice. The rapid and marked
increase in the levels of circulating leptin in the neuronal XBP1-
deficient mice upon HFD feeding indicates an earlier onset of
a higher level of leptin resistance. In complete agreement with
the leptin resistance phenotype, the XNKO mice consume
more food, move significantly less, gain more weight, and
develop significantly higher levels of adiposity and obesity.
Increases in the leptin levels in obesity have been thought to
be proportional to and the result of increased adiposity. Our
results suggest that this might not always be the case, since
regression analysis demonstrates that leptin levels and adiposity
dissociate in the XNKO mice.
While all of the results discussed above provided support to
the hypothesis that ER stress plays a role in the development
of leptin resistance, they also raised a crucial question of whether
the hypothalamic ER stress might be reduced with chemicals
and whether this could be utilized as a strategy to sensitize
obese mice and humans to the anorexigenic effect of leptin.
Chemical chaperones have been previously demonstrated to
be effective in reducing ER stress in different settings, including
peripheral tissues in obesity (Ozcan et al., 2006), cystic fibrosis,
and a1-antitrypsin deficiency (Perlmutter, 2002). PBA and
TUDCA, which are the well-known members of the chemical
chaperone family, also have the ability to reduce ER stress in
the brain. They have been previously implicated as neuroprotec-
tive agents in the neurodegenerative diseases, where ER stress
is considered to be one of the triggering mechanisms for the
pathology (Inden et al., 2007; Petri et al., 2006).
We have shown that PBA and TUDCA pretreatment increase
the leptin sensitivity of both genetic and diet-induced obesity
models. Although high-dose leptin robustly reduces the body
weight of the ob/ob mice, at lower doses, such as 0.1 mg/kg/
day, it is minimally effective. PBA coadministration with either
high or low doses of leptin augments the efficacy of leptin. For
example, coadministration of PBA with only 0.1 mg/kg/day leptin
provides equivalent weight loss to that seen with 1 mg/kg/day
leptin alone, which could be defined as a 10-fold sensitization.
It is also important to note that there is also some degree of ER
stress in the ob/ob mice, and, when they are treated with the
chemical chaperones, leptin efficacy dramatically increases.
Ob/ob mouse model of obesity has always been accepted as
a highly leptin-sensitive mouse model, since leptin administration
does decrease the body weight and suppress the hyperphagia.
However, the leptin doses that are necessary to suppress appe-
tite and decrease the body weight are at supraphysiological
levels. The leptin levels in a WT-lean mouse range between 1
and 4 ng/ml. If we hypothetically think about a 50 g mouse, which
is as leptin sensitive as the WT-lean mouse, the total amount of
leptin that would be sufficient to keep the body weight and hyper-
phagia under control in whole circulation (4–5 ml of blood) would
be 20 ng. Although 0.1 mg/kg leptin accounts for 5000 ng of leptin
for a 50 g mouse, this dose is not capable of decreasing the body
weight of a 50 g ob/ob mouse. The maximum efficiency is seen
between 1 and 5 mg/kg of leptin dose. These doses are 2500
(L) PERK phosphorylation in the hypothalamus extracts.
(M) Leptin-stimulated Stat3Tyr705 phosphorylation in the VEH and PBA-treated HFD-fed mice.
(N) C57BL6 mice were fed a ND for a period of 25 weeks and then either treated with PBA (1 g/kg) or VEH for 16 days. Following the treatment period, mice were
starved for 6 hr and subsequently injected with leptin (IP, 1 mg/kg). Stat3Tyr705 phosphorylation and total Stat levels were examined in the hypothalamus extracts
(n = 6 in each group).
Error bars, ± SEM. p values are determined by Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
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and 5000 times more than the physiological doses, respectively.
Indeed, administration of leptin at 0.1 mg/kg activates the leptin
receptor signaling in the hypothalamus of WT-lean mice, whereas
this effect is totally absent in the ob/ob mouse model. It is also
evident in the previous reports that ob/ob mice have a degree
of leptin resistance. For example, Mistry et al. (1997) have shown
that ICV administration of 50 ng of leptin to ob/ob mice is mini-
mally effective in suppressing the appetite, and they have admin-
istered 1 mg of leptin through the ICV route to obtain significant
effects. That 1 mg of leptin is 50 times higher than the expected
dose of total leptin in the circulation of a 50 g leptin-sensitive
ob/ob mouse model. In addition, although 50 ng of leptin is
almost three times the amount that would be expected to fully
mediate leptin’s effect, it did not at all increase O2 consumption,
which is one of the signatures of leptin action. To further discuss
this issue, we would like to emphasize the insulin resistance of
ob/ob mice. It is well established that ob/ob mice are severely
insulin resistant. Administration of 1 IU/kg of insulin minimally
activates the insulin receptor signaling and cannot lower the
blood glucose levels efficiently. However, if ob/ob mice are
administered with 10 IU/kg of insulin, they will probably face
hypoglycemia. We think that a similar phenomenon holds for
the leptin sensitivity in the ob/ob mice. One more example from
other systems could be the insulin-deficient diabetes models
both in mice and humans. STZ-diabetic mice and type 1 diabetic
patients can develop insulin resistance despite absolute defi-
ciency of insulin. Taking all of these phenomenons and the data
presented in this study into account, we think that it is possible
that overconsumption of nutrients could itself be a reason for
development of leptin resistance independent of prolonged leptin
action. Thus, our data challenge the current concept that pro-
longed leptin exposure due to hyperleptinemia is the initiative
and underlying factor for development of leptin resistance in
obese mice. This line of thinking favors the fact that increased
adiposity and consequent hyperleptinemia decreases the
leptin action and creates the leptin resistance. Our data raise
the possibility that increased UPR signaling even before the
onset of adiposity and hyperleptinemia might be creating
leptin resistance, and it might be the underlying reason for devel-
opment of leptin resistance, since the leptin levels of XNKO mice
severely increase at the early phases of HFD feeding, which are
not proportional to the body weight. It should be also noted
that leptin levels reach to extremely high levels in XNKO mice
during the late phases of HFD feeding. We could not find any
mouse model reported to date whose leptin levels are as high
as the XNKO mice.
While discussed observations above are providing new
insights regarding leptin sensitivity, the most important point is
the ability of both PBA and TUDCA to show the leptin sensitizer
effect in the diet-induced obesity model. In HFD-induced obese
mice, leptin administration leads to an initial reduction in body
weight, but this weight loss is rapidly regained, rendering leptin
as an ineffective antiobesity drug. However, pretreatment of
these mice with the PBA leads to a significant weight loss,
showing that the effect that is seen in ob/ob mice also is also ob-
tained in wild-type, diet-induced obese mice. Having shown that
TUDCA, another chemical chaperone with a completely different
structure than PBA, also increases leptin sensitivity in the ob/ob
and HFD-fed mice provides important evidence that chemical
chaperones in common are leptin sensitizers.
A leptin-sensitizing agent has not been previously described
despite the long-standing efforts in both academia and industry.
The results presented in this study provide evidence that chem-
ical chaperones, particularly the PBA and TUDCA, can be used
as leptin-sensitizing agents. When the high safety profiles of
PBA, TUDCA, and leptin are taken into consideration, our results
may define a novel treatment option for obesity.
EXPERIMENTAL PROCEDURES
Reagents
Phospho-Perk (Thr980), phospho-Stat3 (Tyr705), IRE1 antibodies were from
Cell Signaling Technology (Beverley, MA). Phospho-tyrosine, Jak2, Stat3,
and XBP1 antibodies were obtained from Santa Cruz Biotechnologies (Santa
Cruz, CA). ATF6 was from Abcam (Cambridge, MA). Phospho-IRE1 antibody
was from Novus Biologicals (Littleton, CO). BM chemiluminescence blotting
substrate (POD) was from Roche Diagnostics, Inc. (Indianapolis, IN). PBA
and Tunicamycin were from Calbiochem (San Diego, CA). Dulbecco’s modi-
fied Eagle’s medium (DMEM) was from GIBCO (Grand Island, NY). Humulin
R was from Eli Lilly (Indianapolis, IN). TRIzol reagent and geneticin were
from Invitrogen (Carlsbad, CA). iScript cDNA Synthesis Kit and Syber Green
Fluoresence were obtained from Bio-Rad (Hercules, CA). Plastic cannulas
were from Plastics One, Inc. (Wallingford, CT). Mouse recombinant leptin
was commercially obtained from A.F. Parlow (Harbor-UCLA Medical Center).
Mouse Leptin Elisa Kit and Ultra-Sensitive Mouse Insulin Elisa Kit were from
Crystal Chem, Inc. (Downers Grove, IL).
Cell Culture and Signaling Experiments
Human 293 cells, which were stably transfected with LRb, were cultured in 5%
CO2 incubator in 150 cm
2 cell culture flasks in DMEM-H, which contains 10%
Figure 7. Chemical Chaperone TUDCA Also Acts as a Leptin Sensitizer
(A) Hypothalamic PERK phosphorylation (Thr980) after 21 days of vehicle or TUDCA (150 mg/kg/day) treatment. Following a 5 day pretreatment with TUDCA
(150 mg/kg/day) or vehicle, 9- to 10-week old ob/ob mice were treated either with leptin (1 mg/kg/day) or vehicle.
(B–D) (B) Body weight (g), (C) percent of decrease in body weight, and (D) daily food intake of the ob/obmice during 18 days of treatment period with the indicated
regimens.
(E) Blood glucose (mg/dl) levels at the eighteenth day of treatment. Metabolic cage studies were performed.
(F) CO2 production (ml/kg/hr).
(G) O2 consumption (ml/kg/hr).
(H) Respiratory exchange ratio (VCO2/VO2).
(I) X axis ambulatory activity.
(J) Heat generation (kcal/hr).
(K–M) Dexa scan analysis of (K) total fat amount (g), (L) fat percentage, and (M) lean body mass (g).
(N) C57BL/6 male WT mice were kept on HFD feeding for 32 weeks and, following a 5 day acclimation period, were pretreated with TUDCA (150 mg/kg/day) for
5 days. At the end of the pretreatment period, intraperitoneal vehicle and leptin (1 mg/kg/day) treatments were started. (N) Body weight (g) and (O) percent of
decrease in body weight of the HFD-fed mice during the 16 day treatment (n = 6 for VEH, n = 7 for Lep, n = 7 for TUD, and n = 8 for TUD + Lep group).
Error bars, ± SEM. p values are determined by Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
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ER Stress Causes Leptin Resistancefetal bovine serum (FBS), 1% penicillin-streptomycin complex, and 500 mg/ml
geneticin. After reaching a 90% confluency, cells were passed to 10 cm2 cell
culture dishes at a confluency of 70%. Following 24 hr, cells were washed
three times with DMEM-H medium, which does not contain FBS, and then
taken into incubation with DMEM-H with 1% FBS. After 12–14 hr of incubation
in this medium, cells were exposed to tunicamycin (3 mg/ml, 4 hr) and stimu-
lated with leptin (100 ng/ml) for a period of 45 min. Tunicamycin is dissolved
in DMSO, and stock concentration was 3 mg/ml. To reach to 3 ug/ml, it was
diluted 1000 times. To have the appropriate control, the same amount of
DMSO was added in 1/1000 dilution. At the end of leptin treatment, the
medium was removed and cells were flash frozen in liquid nitrogen and kept
in 80C until further processing.
Analysis of PERK Phosphorylation in the Hypothalamus
Analysis of PERK phosphorylation in tissues is a difficult process, and extreme
precautions are needed for successful detection. To analyze PERK phosphor-
ylation in the hypothalamus, we have combined three hypothalamus and lysed
them in 1 ml of tissue lysis buffer containing 25 mM Tris-HCl (pH 7.4), 10 mM
Na3VO4, 100 mM NaF, 50 mM Na4P2O7, 10 mM EGTA, 10 mM EDTA, 1% NP-
40, 10 ug/ml Leupeptin, 10 ug/ml Aprotinin, 2 mM PMSF, and 20 nM okadaic
acid. Following denaturation in Laemmlie buffer, 300 mg of total protein was
loaded into the wells of the 16 3 16 cm 6% SDS-PAGE gel, and electropho-
resis was performed at 60 V over an 18 hr period. Electrophoresis buffer
was two times changed to have uniform electrophoresis of the samples in
the gel. Following the overnight transfer to the PVDF membrane (45 mM pore
size), the blot has been incubated in blocking solution at room temperature
for 1 hr and taken to overnight antibody incubation in 5% blocking solution
at 1/1000 dilution at 4C. Subsequently, the membranes were washed
with TBST six times for 20 min and taken into secondary antibody incubation
(1/5000 or 1/1000 dilution). Following the secondary antibody incubation,
membranes were washed with TBST ten times for 20 min each, and, subse-
quently, membranes were exposed to the chemiluminisence substrate for
developing the films. Usually more than 20 min of exposing has been neces-
sary to obtain the p-PERK signal (in some of the experiments, we exposed
the membranes 2–3 hr to detect the signal). In the experiments in which
high exposure time has created nonspecific darkening of the films, which inter-
fered with clearly visualizing the p-PERK signal, we have performed overnight
washing and developed the films after this step.
Intracerebro-Ventricular Cannulation and Tunicamycin Infusion
The experiments were carried out on adult, male, 8- to 10-week-old WT
(C57BL/6) mice. The WT mice were implanted with 26 gauge stainless steel
guide cannula into the third ventricle under stereotaxic control using a stereo-
taxic apparatus (coordinates from Bregma: anteroventral, 1.8 mm; lateral,
0.0 mm; dorsoventral, 5.0 mm) through a hole created in the skull with a micro
driller. The cannula was secured to the skull with Crazy Glue and dental cement
and temporarily occluded with a dummy cannula. Triple antibiotic ointment
containing Bacitracin was applied to the interface of the cement and the
skin. Animals were weighed daily, and any animal showing signs of illness or
weight loss was removed from the study and euthanized. At 7 days after ICV
cannulation, WT mice were divided into two groups. The first group of WT
(n = 4) mice was infused with 2 ml of DMSO as a vehicle, and the second group
(n = 4) was infused with 2 ml of tunicamycin (40 mg/ml). All ICV injections were
made through a 31 gauge needle that extended 0.5 mm below the guide
cannula, connected by cannula connector to a 10 ml Hamilton syringe and
infused over 3 min. After 5.5 hr, mice were intraperitoneally treated either
with PBS or leptin (1 mg/kg). At 30 min after leptin administration, hypothal-
amus was dissected and flash frozen in liquid nitrogen and kept in80C until
further processing. For gene expression analysis, hypothalami were dissected
12 hr after tunicamycin and vehicle infusion.
SUPPLEMENTAL DATA
The Supplemental Data for this article include Supplemental Experimental
Procedures and ten figures and can be found with this article online at http://
www.cell.com/cell-metabolism/supplemental/S1550-4131(08)00389-6.
50 Cell Metabolism 9, 35–51, January 7, 2009 ª2009 Elsevier Inc.ACKNOWLEDGMENTS
We thank Laurie H. Glimcher for kindly providing us with the XBP1flox/flox
mouse strain. We thank Eric D. Smith for his editorial advice and help. We
are indebted to Joseph A. Majzoub and Morris F. White for their continuous
support and time for critical reading of our manuscript. We thank Kyle Copps
for critical reading of our manuscript. We thank Mustafa M. Sahin for his kind
advice and discussion of neuronal cell culture and hypothalamic explants
experiments. We thank David Ron for providing us with the PERK/ cells.
This study was supported by junior faculty start-up funds and a Translational
Research Award provided to U.O. from Children’s Hospital Boston and from
Timothy Murphy Funds provided to Division of Endocrinology, Children’s
Hospital Boston.
U.O. conceived the hypothesis, designed the experiments, performed the
experiments, analyzed the data, and wrote the manuscript. L.O. performed
experiments and analyzed data. A.S.E. provided help to U.O. and L.O. for per-
forming experiments. S.S., A.L., and J.C. performed experiments. D.N. per-
formed neuronal culture experiments. M.G.M., Jr. provided LepRB-expressing
293 cell line, LepRB antibody, and helpful comments and advice throughout
the project.
Received: September 26, 2008
Revised: October 26, 2008
Accepted: December 5, 2008
Published: January 6, 2009
REFERENCES
Ahima, R.S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier,
E., and Flier, J.S. (1996). Role of leptin in the neuroendocrine response to
fasting. Nature 382, 250–252.
Banks, W.A. (2003). Is obesity a disease of the blood-brain barrier? Physio-
logical, pathological, and evolutionary considerations. Curr. Pharm. Des. 9,
801–809.
Banks, W.A. (2004). The many lives of leptin. Peptides 25, 331–338.
Bence, K.K., Delibegovic, M., Xue, B., Gorgun, C.Z., Hotamisligil, G.S., Neel,
B.G., and Kahn, B.B. (2006). Neuronal PTP1B regulates body weight, adiposity
and leptin action. Nat. Med. 12, 917–924.
Bjorbak, C., Lavery, H.J., Bates, S.H., Olson, R.K., Davis, S.M., Flier, J.S., and
Myers, M.G., Jr. (2000). SOCS3 mediates feedback inhibition of the leptin
receptor via Tyr985. J. Biol. Chem. 275, 40649–40657.
Chen, W.Y., Bailey, E.C., McCune, S.L., Dong, J.Y., and Townes, T.M. (1997).
Reactivation of silenced, virally transduced genes by inhibitors of histone
deacetylase. Proc. Natl. Acad. Sci. USA 94, 5798–5803.
Elmquist, J.K., Elias, C.F., and Saper, C.B. (1999). From lesions to leptin:
Hypothalamic control of food intake and body weight. Neuron 22, 221–232.
Farooqi, I.S., and O’Rahilly, S. (2005). Monogenic obesity in humans. Annu.
Rev. Med. 56, 443–458.
Flier, J.S. (2004). Obesity wars: Molecular progress confronts an expanding
epidemic. Cell 116, 337–350.
Friedman, J.M., and Halaas, J.L. (1998). Leptin and the regulation of body
weight in mammals. Nature 395, 763–770.
Gao, Q., and Horvath, T.L. (2007). Neurobiology of feeding and energy expen-
diture. Annu. Rev. Neurosci. 30, 367–398.
Halaas, J.L., Gajiwala, K.S., Maffei, M., Cohen, S.L., Chait, B.T., Rabinowitz,
D., Lallone, R.L., Burley, S.K., and Friedman, J.M. (1995). Weight-reducing
effects of the plasma protein encoded by the obese gene. Science 269,
543–546.
Hetz, C., Lee, A.H., Gonzalez-Romero, D., Thielen, P., Castilla, J., Soto, C., and
Glimcher, L.H. (2008). Unfolded protein response transcription factor XBP-1
does not influence prion replication or pathogenesis. Proc. Natl. Acad. Sci.
USA 105, 757–762.
Inden, M., Kitamura, Y., Takeuchi, H., Yanagida, T., Takata, K., Kobayashi, Y.,
Taniguchi, T., Yoshimoto, K., Kaneko, M., Okuma, Y., et al. (2007). Neurode-
generation of mouse nigrostriatal dopaminergic system induced by repeated
Cell Metabolism
ER Stress Causes Leptin Resistanceoral administration of rotenone is prevented by 4-phenylbutyrate, a chemical
chaperone. J. Neurochem. 101, 1491–1504.
Ishida-Takahashi, R., Rosario, F., Gong, Y., Kopp, K., Stancheva, Z., Chen, X.,
Feener, E.P., and Myers, M.G., Jr. (2006). Phosphorylation of Jak2 on Ser(523)
inhibits Jak2-dependent leptin receptor signaling. Mol. Cell. Biol. 26,
4063–4073.
Kloek, C., Haq, A.K., Dunn, S.L., Lavery, H.J., Banks, A.S., and Myers, M.G.,
Jr. (2002). Regulation of Jak kinases by intracellular leptin receptor sequences.
J. Biol. Chem. 277, 41547–41555.
Leibel, R.L., Chung, W.K., and Chua, S.C., Jr. (1997). The molecular genetics of
rodent single gene obesities. J. Biol. Chem. 272, 31937–31940.
Maestri, N.E., Brusilow, S.W., Clissold, D.B., and Bassett, S.S. (1996). Long-
term treatment of girls with ornithine transcarbamylase deficiency. N. Engl.
J. Med. 335, 855–859.
Marciniak, S.J., and Ron, D. (2006). Endoplasmic reticulum stress signaling in
disease. Physiol. Rev. 86, 1133–1149.
Mistry, A.M., Swick, A.G., and Romsos, D.R. (1997). Leptin rapidly lowers food
intake and elevates metabolic rates in lean and ob/ob mice. J. Nutr. 127,
2065–2072.
Muoio, D.M., and Newgard, C.B. (2006). Obesity-related derangements in
metabolic regulation. Annu. Rev Biochem. 75, 367–401.
Myers, M.G., Jr. (2004). Leptin receptor signaling and the regulation of
mammalian physiology. Recent Prog. Horm. Res. 59, 287–304.
Myers, M.G., Jr. (2008). Metabolic sensing and regulation by the hypothal-
amus. Am. J. Physiol. Endocrinol. Metab. 294, E809.
Narayan, K.M., Boyle, J.P., Thompson, T.J., Sorensen, S.W., and Williamson,
D.F. (2003). Lifetime risk for diabetes mellitus in the United States. JAMA 290,
1884–1890.
Ozcan, U., Cao, Q., Yilmaz, E., Lee, A.H., Iwakoshi, N.N., Ozdelen, E.,
Tuncman, G., Gorgun, C., Glimcher, L.H., and Hotamisligil, G.S. (2004).
Endoplasmic reticulum stress links obesity, insulin action, and type 2 dia-
betes. Science 306, 457–461.
Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R.O.,
Gorgun, C.Z., and Hotamisligil, G.S. (2006). Chemical chaperones reduce
ER stress and restore glucose homeostasis in a mouse model of type 2 dia-
betes. Science 313, 1137–1140.Ozcan, U., Ozcan, L., Yilmaz, E., Duvel, K., Sahin, M., Manning, B.D., and Ho-
tamisligil, G.S. (2008). Loss of the tuberous sclerosis complex tumor suppres-
sors triggers the unfolded protein response to regulate insulin signaling and
apoptosis. Mol. Cell 29, 541–551.
Perlmutter, D.H. (2002). Chemical chaperones: A pharmacological strategy for
disorders of protein folding and trafficking. Pediatr. Res. 52, 832–836.
Petri, S., Kiaei, M., Kipiani, K., Chen, J., Calingasan, N.Y., Crow, J.P., and Beal,
M.F. (2006). Additive neuroprotective effects of a histone deacetylase inhibitor
and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral
sclerosis. Neurobiol. Dis. 22, 40–49.
Proulx, K., and Seeley, R.J. (2005). The regulation of energy balance by the
central nervous system. Psychiatr. Clin. North Am. 28, 25–38.
Rocchini, A.P. (2002). Childhood obesity and a diabetes epidemic. N. Engl. J.
Med. 346, 854–855.
Ron, D., and Walter, P. (2007). Signal integration in the endoplasmic reticulum
unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519–529.
Scheuner, D., Vander Mierde, D., Song, B., Flamez, D., Creemers, J.W., Tsu-
kamoto, K., Ribick, M., Schuit, F.C., and Kaufman, R.J. (2005). Control of
mRNA translation preserves endoplasmic reticulum function in beta cells
and maintains glucose homeostasis. Nat. Med. 11, 757–764.
Schroder, M., and Kaufman, R.J. (2005). The mammalian unfolded protein
response. Annu. Rev. Biochem. 74, 739–789.
Schwartz, M.W., and Morton, G.J. (2002). Obesity: Keeping hunger at bay.
Nature 418, 595–597.
Schwartz, M.W., Woods, S.C., Porte, D., Jr., Seeley, R.J., and Baskin, D.G.
(2000). Central nervous system control of food intake. Nature 404, 661–671.
Sola, S., Castro, R.E., Laires, P.A., Steer, C.J., and Rodrigues, C.M. (2003).
Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal
death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol.
Med. 9, 226–234.
Stein, C.J., and Colditz, G.A. (2004). The epidemic of obesity. J. Clin. Endocri-
nol. Metab. 89, 2522–2525.
Zhang, X., Zhang, G., Zhang, H., Karin, M., Bai, H., and Cai, D. (2008). Hypo-
thalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbal-
ance and obesity. Cell 135, 61–73.Cell Metabolism 9, 35–51, January 7, 2009 ª2009 Elsevier Inc. 51
